Neoadjuvant GTX Chemotherapy and IMRT-based Chemoradiation for Borderline Resectable Pancreatic Cancer

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2011 Apr 27

PMID 21520097

Citations 36

Authors

Manish Patel

Sarah Hoffe

Mokenge Malafa

Pamela Hodul

Jason Klapman

Barbara Centeno

Jongphil Kim

James Helm

Tiffany Valone

Gregory Springett

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: To improve the likelihood of achieving a margin-free resection, neoadjuvant induction chemotherapy with GTX (gemcitabine, docetaxel, and capecitabine) followed by 5-FU-IMRT was administered to patients with borderline resectable pancreatic cancer. The utility of computed tomography (CT), endoscopic ultrasound (EUS), positron emission tomography (PET), and CA 19-9 during diagnostic workup and assessment of response was also examined.

Methods: Seventeen patients with borderline resectable pancreatic cancer received a median of three cycles of neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT with dose painting. CA 19-9, CT mass size, and PET SUV were examined before and after neoadjuvant treatment.

Results: Diagnostic EUS and CT scans displayed similar mean mass sizes and extent of vascular involvement. Eight of the 17 patients achieved an R0 resection. Median CA 19-9 levels, CT mass size, and PET SUV all significantly decreased after neoadjuvant therapy. The median progression-free survival and overall survival were 10.48 and 15.64 months, respectively. Six patients are still alive.

Conclusions: Neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT shows promise in improving the likelihood of resectability with negative margins in borderline resectable pancreatic cancer. CT and EUS play complimentary roles during diagnostic workup. CT scans, CA 19-9, and PET scans are useful in judging response to neoadjuvant therapy.

Citing Articles

Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.

Fiore M, Coppola A, Petrianni G, Trecca P, DErcole G, Cimini P J Gastrointest Oncol. 2023; 14(2):1114-1130.

PMID: 37201095 PMC: 10186502. DOI: 10.21037/jgo-22-1034.

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.

Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B JAMA Oncol. 2022; 8(9):1263-1270.

PMID: 35834226 PMC: 9284408. DOI: 10.1001/jamaoncol.2022.2319.

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?.

Wang C, Tan G, Zhang J, Fan B, Chen Y, Chen D Front Oncol. 2022; 12:828223.

PMID: 35785193 PMC: 9245892. DOI: 10.3389/fonc.2022.828223.

Vascular Resections in Association With Pancreatic Resections for Locally Advanced Pancreatic Cancer.

Bacalbasa N, Balescu I, Barbu I, Stiru O, Savu C, Pop L In Vivo. 2022; 36(2):1001-1006.

PMID: 35241562 PMC: 8931869. DOI: 10.21873/invivo.12793.

Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.

Blinn P, Shridhar R, Maramara T, Huston J, Meredith K J Gastrointest Oncol. 2020; 11(5):1078-1089.

PMID: 33209499 PMC: 7657841. DOI: 10.21037/jgo.2019.12.03.

References

Fine R, Fogelman D, Schreibman S, Desai M, Sherman W, Strauss J . The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2007; 61(1):167-75. DOI: 10.1007/s00280-007-0473-0. View

Neoptolemos J, Stocken D, Dunn J, Almond J, Beger H, Pederzoli P . Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001; 234(6):758-68. PMC: 1422135. DOI: 10.1097/00000658-200112000-00007. View

Pingpank J, Hoffman J, Ross E, Cooper H, Meropol N, Freedman G . Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001; 5(2):121-30. DOI: 10.1016/s1091-255x(01)80023-8. View

Safran H, DiPetrillo T, Iannitti D, Quirk D, Akerman P, Cruff D . Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys. 2002; 54(1):137-41. DOI: 10.1016/s0360-3016(02)02902-4. View

Gillen S, Schuster T, Zum Buschenfelde C, Friess H, Kleeff J . Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4):e1000267. PMC: 2857873. DOI: 10.1371/journal.pmed.1000267. View

Crane C, Abbruzzese J, Evans D, Wolff R, Ballo M, Delclos M . Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys. 2002; 52(5):1293-302. DOI: 10.1016/s0360-3016(01)02740-7. View

Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L . Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000; 89(2):314-27. DOI: 10.1002/1097-0142(20000715)89:2<314::aid-cncr16>3.0.co;2-v. View

Millikan K, Deziel D, Silverstein J, Kanjo T, Christein J, Doolas A . Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999; 65(7):618-23; discussion 623-4. View

Li D, Xie K, Wolff R, Abbruzzese J . Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. DOI: 10.1016/S0140-6736(04)15841-8. View

10.

Crane C, Ellis L, Abbruzzese J, Amos C, Xiong H, Ho L . Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006; 24(7):1145-51. DOI: 10.1200/JCO.2005.03.6780. View

11.

Farma J, Santillan A, Melis M, Walters J, Belinc D, Chen D . PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008; 15(9):2465-71. DOI: 10.1245/s10434-008-9992-0. View

12.

Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

13.

Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V . Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004; 28(10):1011-8. DOI: 10.1007/s00268-004-7338-z. View

14.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

15.

Warshaw A, Gu Z, Wittenberg J, Waltman A . Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg. 1990; 125(2):230-3. DOI: 10.1001/archsurg.1990.01410140108018. View

16.

Landry J, Catalano P, Staley C, Harris W, Hoffman J, Talamonti M . Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010; 101(7):587-92. PMC: 4403240. DOI: 10.1002/jso.21527. View

17.

Krishnan S, Rana V, Janjan N, Varadhachary G, Abbruzzese J, Das P . Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110(1):47-55. DOI: 10.1002/cncr.22735. View

18.

Mehta V, Fisher G, Ford J, Poen J, Vierra M, OBERHELMAN H . Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001; 5(1):27-35. DOI: 10.1016/s1091-255x(01)80010-x. View

19.

Hoffman J, Weese J, Solin L, Engstrom P, Agarwal P, Barber L . A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995; 169(1):71-7; discussion 77-8. DOI: 10.1016/s0002-9610(99)80112-3. View

20.

Jessup J, Steele Jr G, Mayer R, Posner M, Busse P, Cady B . Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993; 128(5):559-64. DOI: 10.1001/archsurg.1993.01420170093014. View